Isolated Polycystic Liver Disease

Advances in Chronic Kidney Disease

Volumn 17, Issue 2, 2010, Pages 181-189

  Qian, Qi ^a  

^a Mayo Clinic   (United States)

Author keywords

Interventions for symptomatic cystic liver disease; Isolated polycystic liver disease; Liver cyst related complications

Indexed keywords

ANGIOPEPTIN; EVEROLIMUS; OCTREOTIDE; PLACEBO; RAPAMYCIN;

CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; HEPATOMEGALY; HUMAN; LIVER CYST; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCLEROTHERAPY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY; LIVER DISEASES; MORBIDITY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 77249134582     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2009.12.005     Document Type: Review

References (78)

1. Melnick P.J. Polycystic liver: Analysis of seventy cases. AMA Arch Pathol 59 (1955) 162-172
2. Moschcowitz E. Non-parasitic cysts (congenital) of the liver, with a study of aberrant bile ducts. Am J Med Sci 131 (1906) 674-699
3. Feldman M. Polycystic disease of the liver. Am J Gastroenterol 29 (1958) 83-86
4. Berrebi G., Erickson R.P., and Marks B.W. Autosomal dominant polycystic liver disease: A second family. Clin Genet 21 (1982) 342-347
5. Tahvanainen P., Tahvanainen E., Reijonen H., et al. Polycystic liver disease is genetically heterogeneous: Clinical and linkage studies in eight Finnish families. J Hepatol 38 (2003) 39-43
6. Davila S., Furu L., Gharavi A.G., et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 36 (2004) 575-577
7. Li A., Davila S., Furu L., et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet 72 (2003) 691-703
8. Drenth J.P., te Morsche R.H., Smink R., et al. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 33 (2003) 345-347
9. Trombetta E.S., Fleming K.G., and Helenius A. Quaternary and domain structure of glycoprotein processing glucosidase II. Biochemistry 40 (2001) 10717-10722
10. Skowronek M.H., Rotter M., and Haas I.G. Molecular characterization of a novel mammalian DnaJ-like Sec63p homolog. Biol Chem 380 (1999) 1133-1138
11. Schnell D.J., and Hebert D.N. Protein translocons: Multifunctional mediators of protein translocation across membranes. Cell 112 (2003) 491-505
12. Drenth J.P., Martina J.A., van de Kerkhof R., et al. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med 11 (2005) 37-42
13. Gao H., Wang Y., Wegierski T., et al. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Genet 19 (2004) 16-24
14. von Meyenburg H. Uber die cystenleber. Beitr Path Anat 64 (1918) 477A
15. Bistritz L., Tamboli C., Bigam D., et al. Polycystic liver disease: Experience at a teaching hospital. Am J Gastroenterol 100 (2005) 2212-2217
16. Perrone R.D., Grubman S.A., Rogers L.C., et al. Continuous epithelial cell lines from ADPKD liver cysts exhibit characteristics of intrahepatic biliary epithelium. Am J Physiol 269 (1995) G335-G345
17. Masyuk T., Masyuk A., and LaRusso N. Cholangiociliopathies: Genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol 25 (2009) 265-271
18. Yamaguchi T., Nagao S., Wallace D.P., et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63 (2003) 1983-1994
19. Qian Q., Du H., King B.F., et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19 (2008) 631-638
20. Shillingford J.M., Murcia N.S., Larson C.H., et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103 (2006) 5466-5471
21. Lee S.O., Masyuk T., Splinter P., et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 118 (2008) 3714-3724
22. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
23. Ye M., and Grantham J.J. The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease. N Engl J Med 329 (1993) 310-313
24. Everson G.T., Emmett M., Brown W.R., et al. Functional similarities of hepatic cystic and biliary epithelium: Studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 11 (1990) 557-565
25. Murray S.L., Grubman S.A., Perrone R.D., et al. Matrix metalloproteinase activity in human intrahepatic biliary epithelial cell lines from patients with autosomal dominant polycystic kidney disease. Connect Tissue Res 33 (1996) 249-256
26. Ubara Y. New therapeutic option for autosomal dominant polycystic kidney disease patients with enlarged kidney and liver. Ther Apher Dial 10 (2006) 333-341
27. Bello-Reuss E., Holubec K., and Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 60 (2001) 37-45
28. Nichols M.T., Gidey E., Matzakos T., et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 40 (2004) 836-846
29. Fabris L., Cadamuro M., Fiorotto R., et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 43 (2006) 1001-1012
30. Amura C.R., Brodsky K.S., Groff R., et al. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 293 (2007) C419-C428
31. Alvaro D., Mancino M.G., Onori P., et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 12 (2006) 3537-3545
32. Qian Q., Li A., King B.F., et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 37 (2003) 164-171
33. Sherstha R., McKinley C., Russ P., et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 26 (1997) 1282-1286
34. Alvaro D., Invernizzi P., Onori P., et al. Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 41 (2004) 905-912
35. Alvaro D., Metalli V.D., Alpini G., et al. The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol 43 (2005) 875-883
36. Gigliozzi A., Alpini G., Baroni G.S., et al. Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology 127 (2004) 1198-1209
37. Mancino A., Mancino M.G., Glaser S.S., et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis (2008)
38. Karhunen P.J., and Tenhu M. Adult polycystic liver and kidney diseases are separate entities. Clin Genet 30 (1986) 29-37
39. Everson G.T., Scherzinger A., Berger-Leff N., et al. Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts. Hepatology 8 (1988) 1627-1634
40. Gabow P.A., Johnson A.M., Kaehny W.D., et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 11 (1990) 1033-1037
41. Dmitrewski J., Olliff S., and Buckels J.A. Obstructive jaundice associated with polycystic liver disease. HPB Surg 10 (1996) 117-120
42. Abascal J., Moya M., and Martin F. Infection of hepatic cysts in polycystic disease. World J Surg 8 (1984) 424-425
43. Levine E., Cook L.T., and Grantham J.J. Liver cysts in autosomal-dominant polycystic kidney disease: Clinical and computed tomographic study. AJR Am J Roentgenol 145 (1985) 229-233
44. Levine E., and Grantham J.J. High-density renal cysts in autosomal dominant polycystic kidney disease demonstrated by CT. Radiology 154 (1985) 477-482
45. Dumarey N., Egrise D., Blocklet D., et al. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: Initial experience in 21 patients. J Nucl Med 47 (2006) 625-632
46. Keidar Z., Gurman-Balbir A., Gaitini D., et al. Fever of unknown origin: The role of 18F-FDG PET/CT. J Nucl Med 49 (2008) 1980-1985
47. Bleeker-Rovers C.P., Corstens F.H., Van Der Meer J.W., et al. Fever of unknown origin: Prospective comparison of diagnostic value of (18)F-FDG PET and (111)In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging 31 (2004) 1342-1343
48. Kjaer A., Lebech A.M., Eigtved A., et al. Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging 31 (2004) 622-626
49. Telenti A., Torres V.E., Gross Jr. J.B., et al. Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc 65 (1990) 933-942
50. Schievink W.I., and Spetzler R.F. Screening for intracranial aneurysms in patients with isolated polycystic liver disease. J Neurosurg 89 (1998) 719-721
51. Hoevenaren I.A., Wester R., Schrier R.W., et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 28 (2008) 264-270
52. Reynolds D.M., Falk C.T., Li A., et al. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet 67 (2000) 1598-1604
53. Bae K.T., Zhu F., Chapman A.B., et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 1 (2006) 64-69
54. Harris R.A., Gray D.W., Britton B.J., et al. Hepatic cystic disease in an adult polycystic kidney disease transplant population. Aust N Z J Surg 66 (1996) 166-168
55. Waanders E., van Keimpema L., Brouwer J.T., et al. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int 29 (2009) 1389-1395
56. Tikkakoski T., Makela J.T., Leinonen S., et al. Treatment of symptomatic congenital hepatic cysts with single-session percutaneous drainage and ethanol sclerosis: Technique and outcome. J Vasc Interv Radiol 7 (1996) 235-239
57. Blonski W.C., Campbell M.S., Faust T., et al. Successful aspiration and ethanol sclerosis of a large, symptomatic, simple liver cyst: Case presentation and review of the literature. World J Gastroenterol 12 (2006) 2949-2954
58. Yoshida H., Onda M., Tajiri T., et al. Long-term results of multiple minocycline hydrochloride injections for the treatment of symptomatic solitary hepatic cyst. J Gastroenterol Hepatol 18 (2003) 595-598
59. van Keimpema L., de Koning D.B., Strijk S.P., et al. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Dig Dis Sci 53 (2008) 2251-2257
60. Russell R.T., and Pinson C.W. Surgical management of polycystic liver disease. World J Gastroenterol 13 (2007) 5052-5059
61. Lin T.Y., Chen C.C., and Wang S.M. Treatment of non-parasitic cystic disease of the liver: A new approach to therapy with polycystic liver. Ann Surg 168 (1968) 921-927
62. Farges O., and Bismuth H. Fenestration in the management of polycystic liver disease. World J Surg 19 (1995) 25-30
63. Konstadoulakis M.M., Gomatos I.P., Albanopoulos K., et al. Laparoscopic fenestration for the treatment of patients with severe adult polycystic liver disease. Am J Surg 189 (2005) 71-75
64. Martin I.J., McKinley A.J., Currie E.J., et al. Tailoring the management of nonparasitic liver cysts. Ann Surg 228 (1998) 167-172
65. Schnelldorfer T., Torres V.E., Zakaria S., et al. Polycystic liver disease: A critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 250 (2009) 112-118
66. Robinson T.N., Stiegmann G.V., et al. Laparoscopic palliation of polycystic liver disease. Surg Endosc 19 (2005) 130-132
67. Que F., Nagorney D.M., Gross Jr. J.B., et al. Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology 108 (1995) 487-494
68. Takei R., Ubara Y., Hoshino J., et al. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 49 (2007) 744-752
69. Ubara Y., Takei R., Hoshino J., et al. Intravascular embolization therapy in a patient with an enlarged polycystic liver. Am J Kidney Dis 43 (2004) 733-738
70. Grams J., Teh S.H., Torres V.E., et al. Inferior vena cava stenting: a safe and effective treatment for intractable ascites in patients with polycystic liver disease. J Gastrointest Surg 11 (2007) 985-990
71. Mudge D.W., Taylor J., and Bannister K.M. Hepatic vein stenting for recurrent ascites in polycystic liver and kidney disease. Nephrol Dial Transplant 20 (2005) 2566-2568
72. US Scientific Registry of Transplant: 2004 OPTN/SRTR Annual Report: US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Available at: www.ustransplant.org. Accessed December 30, 2009
73. Alvaro D., Onori P., Alpini G., et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol 172 (2008) 321-332
74. Banales J.M., Masyuk T.V., Bogert P.S., et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 173 (2008) 1637-1646
75. Banales J.M., Masyuk T.V., Gradilone S.A., et al. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 49 (2009) 160-174
76. Masyuk T.V., Masyuk A.I., Torres V.E., et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 132 (2007) 1104-1116
77. van Keimpema L., and Drenth J.P. Effect of octreotide on polycystic liver volume. Liver Int (2009) [Epub ahead of print]
78. van Keimpema L., Nevens F., Vanslembrouck R., et al. Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial. Gastroenterology 137 (2009) 1661-1668